- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04443829
Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma (CAROUSEL)
Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary Central Nervous System (CNS) Lymphoma
The CAROUSEL Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age ≥16) with relapsed/refractory Primary CNS Lymphoma.
The study will evaluate the feasibility of generating the ATIMP, the safety of administering CD19CAR T-cell therapy and how effectively CD19CAR T-cells engraft, expand and persist following administration in patients with relapsed/refractory primary CNS lymphoma.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The CAROUSEL Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age ≥16) with relapsed/refractory Primary CNS Lymphoma. The ATIMP for this study is cryopreserved autologous patient-derived T-cells transduced with CD19CAR vector to generate CD19CAR T-cells.
Patients will undergo an unstimulated leucapheresis for the generation of the ATIMP which will take approximately 15 days to generate. During this period, patients may receive "holding" chemotherapy as per institutional practice to maintain disease control. Patients will receive pre-conditioning lymphodepleting (LD) chemotherapy with cyclophosphamide 60mg/kg on Day -6, fludarabine 30mg/m2 administered over 3 days (Day -5 to Day -3) and pembrolizumab 200mg on Day -1.
All patients will be treated on Theme 1 of the study with 250 x 10^6 CD19 CAR T-cells i.v. following LD chemotherapy as described above. Patients with response of Stable Disease (SD) or Progressive Disease (PD) at Day 28 (or frank relapse beyond Day 28) and in the absence of severe toxicity related to the ATIMP, will be potentially eligible for Theme 2 of the study where they can receive Dose 2, a single dose of 25 x 10^6 CD19CAR T-cells intraventricularly via an Ommaya reservoir following LD chemotherapy as described above.
The study will evaluate the feasibility of generating the ATIMP, the safety of administering CD19CAR T-cell therapy and how effectively CD19CAR T-cells engraft, expand and persist following administration in patients with relapsed/refractory primary CNS lymphoma.
Following infusion of CD19CAR T-cell therapy patients will be monitored for between 2-4 weeks as an inpatient. Following discharge, patients will enter the interventional follow up phase and be followed up for 2 years. Patients will be seen monthly for the first 6 months, then 6 weekly to 12 months and then 3 monthly until 2 years post CD19CAR T-cell infusion.
If patients relapse within the first 2 years post CD19CAR T-cell infusion they will come off the interventional follow up and will be followed up annually until the end of trial is declared.
After completing the interventional phase of the study all patients, irrespective of whether they progressed or responded to treatment, will enter long term follow up until the end of trial is declared.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: CAROUSEL Trial Coordinator
- Phone Number: 02076799860
- Email: ctc.carousel@ucl.ac.uk
Study Locations
-
-
-
London, United Kingdom, WC1E6BT
- University College London Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥16
- Patients with a histologically confirmed Diffuse Large B-Cell Lymphoma (DLBCL) confined to the CNS (Primary CNS Lymphoma (PCNSL))
- Relapsed* or refractory CD19+ PCNSL, defined as disease progression following CR/CRu/PR, or failure to achieve PR, after one or more lines of a high-dose methotrexate-containing protocol *Histological confirmation by re-biopsy at relapse is recommended if feasible. However, patients will be eligible without re-biopsy provided the initial diagnostic material is available and current MRI imaging features are consistent with PCNSL by neuroradiology review.
- Measurable disease on contrast-enhanced MRI
- Unsuitable for alternative salvage therapies as determined by their treating physician
- Agreement to have a pregnancy test, use highly effective contraception (if applicable)
- Written informed consent** ** Some patients with PCNSL may be incapable of providing their own consent due to the neurological effects of their disease. In these cases a legal representative may be sought to provide consent'.
Exclusion Criteria (Registration):
- CD19 negative disease
- Evidence of secondary CNS lymphoma
- Prior allogeneic haematopoietic stem cell transplant
- Active hepatitis B, C or HIV infection
- Oxygen saturation ≤90% on air
- Bilirubin >2 x upper limit of normal
- Glomerular Filtration Rate (GFR) <50ml/min
- Women who are pregnant or breast feeding
- Inability to tolerate leucapheresis
- ECOG 3-4
- Known allergy to albumin or Dimethyl sulfoxide (DMSO)
- Life expectancy <3months
- Arrhythmias or significant cardiac disease and left ventricular ejection fraction <40%
- Pre-existing neurological disorders (other than CNS involvement of underlying haematological malignancy)
- Any contraindications to PD-1 antibody Pembrolizumab
- History of autoimmune disease (e.g. Crohn's, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 24 months
- Evidence of active pneumonitis on chest computed tomography (CT) or positron emission tomography (PET)-CT scan at screening or history of drug-induced pneumonitis, idiopathic pulmonary fibrosis, organising pneumonia (e.g. bronchiolitis obliterans), or idiopathic pneumonitis. Prior radiation pneumonitis in the radiation field (fibrosis) is allowed (if >24 weeks since the event)
Exclusion criteria: for CD19CAR T-cell infusion ( Dose 1/i.v. and Dose 2/intraventricular):
- Severe intercurrent infection at the time of scheduled CD19CAR T-cell infusion
- Requirement for supplementary oxygen or active pulmonary infiltrates at the time of scheduled CD19CAR T-cell infusion
Theme 2 only:
- presence of grade 3 or 4 ICANS casually related to the ATIMP following infusion of Dose 1
- grade 1-2 neurotoxicity (if occurred) following Theme 1 dosing (Dose 1/i.v CD19CAR Tcell dose) that has not fully resolved prior to proposed administration of 2nd CD19CAR T-cell infusion (Dose /intraventricular) for theme 2
- grade 3-4 CRS following infusion of Dose 1
- persisting grade 2 CRS following Theme 1 dosing (Dose 1/i.v CD19CAR T-cell dose) that has not resolved to ≤ grade 1 CRS prior to proposed administration of 2nd CD19CAR Tcell infusion (Dose 2/intraventricular) for theme 2
- pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CD19CAR T-cells
Treatment with the ATIMP: CD19CAR T-cells
|
Infusion with: CD19CAR T-cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity evaluated by the incidence of grade 3-5 toxicity causally related to the ATIMP
Time Frame: 28 days
|
Toxicity following CD19CAR T-cell administration as evaluated by the incidence of grade 3-5 toxicity causally related to the ATIMP
|
28 days
|
Feasibility of manufacturing CD19CAR T-cells evaluated by the number of therapeutic products generated
Time Frame: 28 days
|
Feasibility of adequate leucapheresis collection and generation of CD19CAR T-cells as evaluated by the number of therapeutic products generated.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response at 1 and 3 months
Time Frame: From CD19CAR T-cells infusion to 1 and 3 months
|
Proportion of patients achieving a Complete Response (CR) or Partial Response (PR) at 1 and 3 months post CD19CAR T-cells infusion: Theme 1 (i.v.) and Theme 2 (intraventricular)
|
From CD19CAR T-cells infusion to 1 and 3 months
|
Frequency of circulating CD19CAR T-cells in peripheral blood
Time Frame: From CD19CAR T-cells infusion up to 2 years post CD19CAR T-cells infusion
|
Frequency of circulating CD19CAR T-cells in peripheral blood as assessed by flow cytometry and qPCR
|
From CD19CAR T-cells infusion up to 2 years post CD19CAR T-cells infusion
|
Incidence of B-cell aplasia
Time Frame: From CD19CAR T-cells infusion up to 2 years post CD19CAR T-cells infusion
|
Incidence of B-cell aplasia
|
From CD19CAR T-cells infusion up to 2 years post CD19CAR T-cells infusion
|
Relapse rate at 1 and 2 years
Time Frame: At 1 year and 2 years after CD19CAR T-cells infusion
|
Proportion of patients who have relapsed at 1 and 2 years after CD19CAR T-cells infusion
|
At 1 year and 2 years after CD19CAR T-cells infusion
|
Progression Free Survival (PFS) at 1 and 2 years
Time Frame: At 1 year and 2 years after CD19CAR T-cells infusion
|
Progression Free Survival at 1 and 2 years after CD19CAR T-cells infusion
|
At 1 year and 2 years after CD19CAR T-cells infusion
|
Overall Survival (OS) at 1 and 2 years
Time Frame: At 1 year and 2 years after CD19CAR T-cells infusion
|
Overall Survival at 1 and 2 years after immunotherapy with CD19CAR T-cells infusion
|
At 1 year and 2 years after CD19CAR T-cells infusion
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Claire Roddie, University College London Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UCL/126892
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary CNS Lymphoma
-
Matthew J. Frigault, M.D.NovartisRecruitingPrimary CNS Lymphoma | Refractory Primary CNS Lymphoma | Relapsed Primary CNS LymphomaUnited States
-
Mingzhi ZhangZhengzhou UniversityUnknown
-
Mingzhi ZhangZhengzhou UniversityCompleted
-
Huiqiang HuangGuangdong 999 Brain HospitalNot yet recruitingNon Hodgkin Lymphoma | PCNSL | Refractory and Relapsed Primary CNS LymphomaChina
-
Ono Pharmaceutical Co. LtdRecruitingPrimary CNS Lymphoma | Refractory Primary Central Nervous System LymphomaUnited States
-
Charite University, Berlin, GermanyPfizerUnknownRecurrent or Refractory Primary CNS LymphomaGermany
-
Guangdong Provincial People's HospitalUnknownPrimary CNS LymphomaChina
-
Singapore General HospitalNational University Hospital, Singapore; National Cancer Center Singapore,... and other collaboratorsWithdrawnEBV Related Non-Hodgkin's Lymphoma | Primary CNS Lymphoma | Primary Testicular LymphomaSingapore
-
Rabin Medical CenterJanssen, LPRecruitingCentral Nervous System LymphomaIsrael
-
National Research Center for Hematology, RussiaRecruitingPrimary CNS LymphomaRussian Federation
Clinical Trials on CD19CAR T-cells
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingB Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic LeukemiaUnited States
-
University of Colorado, DenverNational Cancer Institute (NCI)RecruitingB-cell Acute Lymphoblastic Leukemia | B-cell Non Hodgkin LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Recurrent Non-Hodgkin LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Active, not recruitingB Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic LeukemiaUnited States
-
Everett MeyerNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedLymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Acute Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myelodysplastic Syndromes (MDS) | Acute Lymphoblastic Leukemia (ALL) | Myeloid Leukemia, Chronic | Myeloproliferative SyndromeUnited States
-
Sorrento Therapeutics, Inc.WithdrawnBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreas Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Carcinoembryonic AntigenUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityEureka Therapeutics Inc.Unknown